Watch the cPass video to learn how it works
Reagents
cPass SARS-CoV-2 Neutralization Antibody Detection Kit (CE, US FDA EUA, HSA, ANVISA)
cPass Neutralization Antibody Detection kit detects circulating neutralizing antibodies against SARS-CoV-2 that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein with the ACE2 cell surface receptor. This kit would be instrumental in vaccine and therapeutic development as it is suitable for all antibody isotypes and can be used to determine neutralizing antibodies in animal models without modification. The kit will also help in current COVID-19 investigations of sero-prevalence, assessment of herd immunity, longevity of protective immunity, efficacy of different vaccine candidates as well as tracking infection in animals.Neutralization Antibody Detection kit has acquired CE mark (Europe), US FDA Emergency Use Authorization, HSA provisional approval (Singapore) and ANVISA authorization (Brazil).
- Global patent protection for the kit will be firmly implemented.
- 96 well ELISA format test with ACE2 protein attached to the plate and HRP labeled RBD is used for detection.
- Can be used with serum and plasma samples.
- The kit comes with positive and negative controls.
- 4 wells are typically used for the controls, so 92 wells can be used for samples.
